Cell cycle arrest of cardiomyocytes in the context of cardiac regeneration

Qingling Xu, Xinhui Chen, Chenchen Zhao, Ying Liu, Jianxun Wang, Xiang Ao, Wei DingFrontiers in Cardiovascular Medicine 2025 · DOI

TL;DR

Adult mammalian hearts are notoriously bad at self-repair because their muscle cells (cardiomyocytes) permanently exit the cell cycle shortly after birth. This review synthesizes recent breakthroughs in genetic, metabolic, and signaling research to identify the "molecular brakes" of the heart and explores how we might flip the switch to induce regeneration after injury.

What Problem Does This Paper Address?

Unlike zebrafish or salamanders, which can regrow entire sections of their hearts, adult humans respond to cardiac injury (like a myocardial infarction) by forming irreversible scar tissue. This lack of regenerative capacity is the primary driver of heart failure.

The "window of opportunity" for regeneration in mammals is incredibly narrow—in mice, it slams shut just seven days after birth. This paper investigates why this happens. The authors tackle the complex interplay of factors that force cardiomyocytes into permanent cell cycle arrest, aiming to identify therapeutic targets that could force these cells back into a proliferative state to replace lost muscle.

Methods

As a comprehensive review article, the authors systematically synthesized findings from over 180 recent studies (up to early 2025). They categorized the mechanisms of cardiomyocyte cell cycle arrest into four primary pillars:

  1. Genetic Regulation: The role of specific coding genes (like Meis1 and Hoxb13) and cell cycle inhibitors (p21, p27).
  2. Non-coding RNAs: How miRNAs, lncRNAs, and circRNAs act as "rheostats" for cell division.
  3. Signaling Pathways: The tug-of-war between growth-promoting pathways (Notch) and growth-inhibiting pathways (Hippo-YAP, TGF-β).
  4. Metabolic Reprogramming: The shift from fetal glycolysis to adult fatty acid oxidation as a trigger for arrest.

Datasets

Not discussed in the paper (this is a review of existing literature rather than a primary experimental study).

Key Insights and Ideas

  • The Oxygen Paradox: The very thing that sustains adult life—oxygen—is a primary cause of cell cycle arrest. The transition from the low-oxygen environment of the womb to the oxygen-rich postnatal world triggers mitochondrial oxidative phosphorylation. This produces Reactive Oxygen Species (ROS), which cause DNA damage and activate the DNA Damage Response (DDR), effectively locking the cell cycle "gate."
  • Metabolism as a Master Regulator: There is a profound link between what a cell eats and if it can divide. Adult cardiomyocytes primarily burn fatty acids, which promotes arrest. Experimental evidence shows that forcing cells back toward a "fetal" glycolytic metabolism can re-open the proliferative window.
  • The Hippo-YAP Brake: The Hippo signaling pathway emerges as a major negative regulator. When Hippo is active, it prevents the protein YAP from entering the nucleus. If researchers can inhibit Hippo or overexpress YAP, they can successfully stimulate adult cardiomyocytes to re-enter the cell cycle.
  • RNA Fine-Tuning: Non-coding RNAs are not "junk." For example, the miR-15 family is upregulated shortly after birth and actively represses cell cycle genes. Silencing these RNAs has shown promise in extending the regenerative window in animal models.

Key Results

  • Renewal Rates: The paper highlights that human cardiomyocyte renewal is a meager 1% annually at age 25, dwindling to just 0.45% by age 75.
  • Metabolic Reversal: Inhibiting enzymes like CPT1 (involved in fatty acid oxidation) has been shown to transition cardiomyocytes to an immature metabolic state, successfully triggering cell cycle re-entry in mice.
  • Clinical Translation: The authors provide a roadmap of current drugs (see Table 2 in the paper) like Trimetazidine and Ranolazine. While originally designed for angina or heart failure, these drugs are now being re-evaluated for their ability to modulate the metabolic pathways that govern the cell cycle.

Limitations and Future Work

  • Redundancy: The cell cycle is protected by multiple, redundant "brakes." Knocking out a single gene (like Meis1) often only provides a temporary boost in proliferation before other mechanisms take over. A "cocktail" approach targeting multiple pathways simultaneously is likely required.
  • The Cancer Risk: The biggest hurdle in regenerative medicine is safety. Forcing adult cells to divide carries an inherent risk of uncontrolled proliferation (oncogenesis). Future work must focus on "transient" activation—flipping the switch on for repair and then safely flipping it off.
  • Species Gap: Most "breakthroughs" currently exist in zebrafish or neonatal mice. Translating these findings into the complex, aged, and often co-morbid environment of a human heart remains the ultimate challenge for the next decade of cardiovascular research.

Summary updated

Abstract

The limited capacity of adult mammalian cardiomyocytes to undergo cell division and proliferation is one of the key factors contributing to heart failure. In newborn mice, cardiac proliferation occurs during a brief window, but this proliferative capacity diminishes by 7 days after birth. Current studies on cardiac regeneration focused on elucidating changes in regulatory factors within the heart before and after this proliferative window, aiming to determine whether potential association between these factors and cell cycle arrest in cardiomyocytes. Facilitating the re-entry of cardiomyocytes into the cell cycle or reversing their exit from it represents a critical strategy for cardiac regeneration. This paper provides an overview of the role of cell cycle arrest in cardiac regeneration, briefly describes cardiomyocyte proliferation and cardiac regeneration, and systematically summarizes the regulation of the cell cycle arrest in cardiomyocytes, and the potential metabolic mechanisms underlying cardiomyocyte cycle arrest. Additionally, we highlight the development of cardiovascular disease drugs targeting cardiomyocyte cell cycle regulation and their status in clinical treatment. Our goal is to outline strategies for promoting cardiac regeneration and repair following cardiac injury, while also pointing toward future research directions that may offer new technologies and prospects for treating cardiovascular diseases, such as myocardial infarction, arrhythmia and heart failure.
BibTeX
@inproceedings{xu2025cell,
  author = {Qingling Xu and Xinhui Chen and Chenchen Zhao and Ying Liu and Jianxun Wang and Xiang Ao and Wei Ding},
  title = {{Cell cycle arrest of cardiomyocytes in the context of cardiac regeneration}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2025},
  doi = {10.3389/fcvm.2025.1538546},
}
Figure